MedTrace Logo

MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5

NCT01121237 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2086

Last updated 2016-04-06

No results posted yet for this study

Summary

MONITOR-CKD5 is an observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the treatment of renal anaemia with biosimilar epoetin alfa in Stage 5 CKD patients requiring haemodialysis.

Conditions

Interventions

DRUG

Recombinant human erythropoietin alfa (biosimilar)

Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician

Sponsors & Collaborators

  • Hexal AG

    collaborator INDUSTRY

  • Sandoz

    lead INDUSTRY

Principal Investigators

  • HEXAL AG · Hexal AG

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Austria
  • France
  • Germany
  • Italy
  • Poland
  • Romania
  • Slovenia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01121237 on ClinicalTrials.gov